A late study that was published in August in the “Journal of Nuclear Medicine”, a group of researchers at the Michigan’s University, have stated the first ever in human application of a new PET tracer for prostate cancer.
They have explained the possibility of this new PET radio-tracer, labelled as Carbon-11-sarcosine (11C-sarcosine), for making a representation of the prostate cancer and set the platform for its usage possibility in monitoring other cases of cancer.
This new study reveals the comparison of effectiveness of this PET tracer with 11C-choline, which is already in wide use for prostate cancer imaging, in two models of mouse, also performing the first two PET/CT scan with the 11C-sarcosine with a prostate cancer of a human.
According to the CDC or the “Centres for Disease Control”, prostate is the second deadliest human cancer among males. Sarcosine plays a significant role in its progression and aggressiveness. It is through amino acid transporters that are proton-coupled, the Sarcosine enters the cell, which are over expressed in solid tumours or selected tissues-making it a great target of imaging.
The team also unfolded that the PET tracer with its nature of dual receptor targeting has advantages over targeting single-receptor that allows tumour contrast when both the receptor types and either one of them are expressed. This further improves the binding affinity and also maximises the number of effective receptors.
Piert states that for characterizing and identifying other cancers this 11C-sarcosine could be a significant tracer. According to their knowledge this is so far the first radio-tracer that interrogated with the activity of PATs, which plays a role of varied purpose carriers in different cells with distinctive roles. In certain cases PATs also play vital role as a drug transporter and nutrients, in the intestinal tract.
Piert further adds that, with cell proliferation PAT expression also increases. In cancer, the function of the PAT has been related to the sensing engine of amino-acid that riggers activation of the rapamycin complex 1’s mammalian target (mTORC1), which is a new anti-cancer drugs and new target of existing. Though more studies are required for further validation, yet this Sarcosine could be useful for monitoring the targeted cancer treatments of the mTORC1.